Xiaobin Xu

Xiaobin Xu, PhD, MBA, is a seasoned professional in the biotech and healthcare investment sectors, currently serving as a Senior Equity Research Associate at AB Bernstein since April 2024, focusing on US Large Cap Biopharma. Previously, Xiaobin held the position of Biotech/Healthcare Investment Analyst at Matthews Asia from January 2022 to December 2023, where responsibilities included authoring investment research reports, initiating portfolio positions, and conducting financial modeling. Prior experience at Regeneron from October 2013 to January 2022 as a Senior Principal Scientist involved leading a team in drug development, authoring regulatory submissions, and advancing multiple drugs to market. Xiaobin's educational background includes an MBA with Dean's Honors from Columbia Business School and a PhD in Chemistry from Boston University, along with Master's and Bachelor's degrees in Chemistry from Sichuan University.